Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.
Saved in:
| Title: | Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. |
|---|---|
| Authors: | Bosaeed M; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia., Balkhy HH; World Health Organization, Geneva, Switzerland., Almaziad S; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia., Aljami HA; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Alhatmi H; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia., Alanazi H; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Alahmadi M; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Jawhary A; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Alenazi MW; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Almasoud A; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Alanazi R; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Bittaye M; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Aboagye J; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Albaalharith N; Department of Nursing, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia., Batawi S; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Folegatti P; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Ramos Lopez F; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Ewer K; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Almoaikel K; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Aljeraisy M; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Alothman A; Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; Department of Medicine, King Abdulaziz Medical City in Riyadh, Riyadh, Saudi Arabia., Gilbert SC; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Khalaf Alharbi N; Vaccine Development Unit, Infectious Disease Research Department, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. |
| Source: | The Lancet. Microbe [Lancet Microbe] 2022 Jan; Vol. 3 (1), pp. e11-e20. Date of Electronic Publication: 2021 Nov 03. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
